Generalised Reduction of Putative Endothelial Progenitors and CXCR4-positive Peripheral Blood Cells in Type 2 Diabetes

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2008 Feb 21

PMID 18286257

Citations 58

Authors

C G Egan

R Lavery

F Caporali

C Fondelli

F Laghi-Pasini

F Dotta

V Sorrentino

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: In patients with type 2 diabetes, reduced levels of circulating endothelial progenitor cells have been reported and these have been correlated with disease severity. In this study, we examined a panel of markers widely used to identify progenitor and/or stem cells, and determined their association with disease severity in diabetic patients. Since expression of chemokine (C-X-C motif) receptor 4 (CXCR4) has been associated with mobilisation and recruitment of progenitor cells, CXCR4 expression was also analysed.

Methods: Peripheral blood mononuclear cells (PBMCs) from 98 patients with type 2 diabetes and 39 control individuals were analysed by flow cytometry for surface marker expression.

Results: Cells expressing different combinations of progenitor and/or stem cell markers were severely reduced in PBMCs of diabetic patients compared with those of control participants. Moreover, a number of these putative progenitor cell populations were negatively associated with disease severity. Reduced expression of CXCR4 and CD34/CXCR4-positive cells was also observed in diabetic patients. PBMCs expressing CXCR4 positively correlated with levels of progenitor cells in control participants but not in diabetic patients. Levels of putative progenitor and CXCR4-positive cells were further decreased in patients with diabetic complications, including cardiovascular and microvascular diseases.

Conclusions/interpretation: A generalised decrease in a range of progenitor cell populations was observed in type 2 diabetic patients. This reduction was also negatively associated with disease severity.

Citing Articles

Association of vitamin D and bisphenol A levels with cardiovascular risk in an elderly Italian population: results from the InCHIANTI study.

Brandi M, Marini F, Parri S, Bandinelli S, Iantomasi T, Giusti F Geroscience. 2024; 46(6):6141-6156.

PMID: 38837025 PMC: 11494005. DOI: 10.1007/s11357-024-01193-1.

Endothelial progenitor cells for diabetic cardiac and kidney disease.

Raleigh M, Pasricha S, Nauth A, Ward M, Connelly K Stem Cells Transl Med. 2024; 13(7):625-636.

PMID: 38733609 PMC: 11227977. DOI: 10.1093/stcltm/szae025.

Human Cord Blood Endothelial Progenitor Cells and Pregnancy Complications (Preeclampsia, Gestational Diabetes Mellitus, and Fetal Growth Restriction).

Kwon J, Maeng Y Int J Mol Sci. 2024; 25(8).

PMID: 38674031 PMC: 11050478. DOI: 10.3390/ijms25084444.

Endothelial progenitor cells as biomarkers of diabetes-related cardiovascular complications.

Benitez-Camacho J, Ballesteros A, Beltran-Camacho L, Rojas-Torres M, Rosal-Vela A, Jimenez-Palomares M Stem Cell Res Ther. 2023; 14(1):324.

PMID: 37950274 PMC: 10636846. DOI: 10.1186/s13287-023-03537-8.

Bone marrow vasculature advanced models for cancer and cardiovascular research.

Campanile M, Bettinelli L, Cerutti C, Spinetti G Front Cardiovasc Med. 2023; 10:1261849.

PMID: 37915743 PMC: 10616801. DOI: 10.3389/fcvm.2023.1261849.

References

Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H . Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001; 89(1):E1-7. DOI: 10.1161/hh1301.093953. View

Fadini G, Sartore S, Agostini C, Avogaro A . Significance of endothelial progenitor cells in subjects with diabetes. Diabetes Care. 2007; 30(5):1305-13. DOI: 10.2337/dc06-2305. View

. Standards of medical care in diabetes--2007. Diabetes Care. 2006; 30 Suppl 1:S4-S41. DOI: 10.2337/dc07-S004. View

Grisar J, Aletaha D, Steiner C, Kapral T, Steiner S, Seidinger D . Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation. 2005; 111(2):204-11. DOI: 10.1161/01.CIR.0000151875.21836.AE. View

Loomans C, de Koning E, Staal F, Rookmaaker M, Verseyden C, de Boer H . Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes. 2003; 53(1):195-9. DOI: 10.2337/diabetes.53.1.195. View

Lee I, Chae S, Kim J . Involvement of circulating endothelial progenitor cells and vasculogenic factors in the pathogenesis of diabetic retinopathy. Eye (Lond). 2005; 20(5):546-52. DOI: 10.1038/sj.eye.6701920. View

Gallagher K, Liu Z, Xiao M, Chen H, Goldstein L, Buerk D . Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest. 2007; 117(5):1249-59. PMC: 1857264. DOI: 10.1172/JCI29710. View

Urbich C, Dimmeler S . Endothelial progenitor cells: characterization and role in vascular biology. Circ Res. 2004; 95(4):343-53. DOI: 10.1161/01.RES.0000137877.89448.78. View

Butler J, Guthrie S, Koc M, Afzal A, Caballero S, Brooks H . SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J Clin Invest. 2005; 115(1):86-93. PMC: 539202. DOI: 10.1172/JCI22869. View

10.

Damas J, Waehre T, Yndestad A, Ueland T, Muller F, Eiken H . Stromal cell-derived factor-1alpha in unstable angina: potential antiinflammatory and matrix-stabilizing effects. Circulation. 2002; 106(1):36-42. DOI: 10.1161/01.cir.0000020001.09990.90. View

11.

Fadini G, Miorin M, Facco M, Bonamico S, Baesso I, Grego F . Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005; 45(9):1449-57. DOI: 10.1016/j.jacc.2004.11.067. View

12.

Fadini G, Sartore S, Baesso I, Lenzi M, Agostini C, Tiengo A . Endothelial progenitor cells and the diabetic paradox. Diabetes Care. 2006; 29(3):714-6. DOI: 10.2337/diacare.29.03.06.dc05-1834. View

13.

Stumvoll M, Goldstein B, van Haeften T . Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005; 365(9467):1333-46. DOI: 10.1016/S0140-6736(05)61032-X. View

14.

Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M . Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999; 5(4):434-8. DOI: 10.1038/7434. View

15.

Molitch M, DeFronzo R, Franz M, Keane W, Mogensen C, Parving H . Nephropathy in diabetes. Diabetes Care. 2003; 27 Suppl 1:S79-83. DOI: 10.2337/diacare.27.2007.s79. View

16.

Isner J, Asahara T . Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest. 1999; 103(9):1231-6. PMC: 408362. DOI: 10.1172/JCI6889. View

17.

Vita J . Endothelial function and clinical outcome. Heart. 2005; 91(10):1278-9. PMC: 1769130. DOI: 10.1136/hrt.2005.061333. View

18.

Waltenberger J . Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res. 2001; 49(3):554-60. DOI: 10.1016/s0008-6363(00)00228-5. View

19.

St Clair L, Ballantyne C . Biological surrogates for enhancing cardiovascular risk prediction in type 2 diabetes mellitus. Am J Cardiol. 2007; 99(4A):80B-88B. DOI: 10.1016/j.amjcard.2006.11.008. View

20.

Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110(2):227-39. DOI: 10.1161/01.CIR.0000133317.49796.0E. View